Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Wingless-type MMTV integration site family, member 3 (WNT3) is a secreted glycoprotein belonging to the Wnt family, acting as a ligand in canonical Wnt/β-catenin signaling. WNT3 plays critical roles in embryonic development, particularly in axis formation, pattern specification, and organogenesis. It binds to cell-surface Frizzled G protein–coupled receptors and co-receptors LRP5/6 to activate downstream signaling, leading to stabilization and nuclear translocation of β-catenin and consequent transcriptional activation of target genes. In adults and pathologic contexts, WNT3 contributes to stem cell maintenance, tissue regeneration, and has strong associations with oncogenesis—including colorectal, breast, lung, and gastric cancer—through aberrant pathway activation. Dysregulation of WNT3 can contribute to both tumor progression and resistance to targeted therapies via effects on cell proliferation, migration, and apoptosis[1][3][4][5].
Inhibition of Wnt ligand secretion (via PORCN inhibitors); Decoy receptors or antibodies targeting components of the Wnt-Frizzled-LRP5/6 complex can block signaling[5].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wingless-type MMTV integration site family, member 3 (WNT3).